Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N3XP
|
|||
| Former ID |
DIB019890
|
|||
| Drug Name |
G749
|
|||
| Synonyms |
G-749
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C25H25BrN6O2
|
|||
| Canonical SMILES |
CN1CCC(CC1)NC2=NC3=C(C(=O)NC=C3Br)C(=N2)NC4=CC=C(C=C4)OC5=CC=CC=C5
|
|||
| InChI |
1S/C25H25BrN6O2/c1-32-13-11-17(12-14-32)29-25-30-22-20(26)15-27-24(33)21(22)23(31-25)28-16-7-9-19(10-8-16)34-18-5-3-2-4-6-18/h2-10,15,17H,11-14H2,1H3,(H,27,33)(H2,28,29,30,31)
|
|||
| InChIKey |
SXWMIXPJPNCXQQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1457983-28-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fms-like tyrosine kinase 3 (FLT-3) | Target Info | Inhibitor | [1] |
| Tyrosine-protein kinase Mer (MERTK) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Hematopoietic cell lineage | ||||
| Pathways in cancer | ||||
| Transcriptional misregulation in cancer | ||||
| Acute myeloid leukemia | ||||
| Central carbon metabolism in cancer | ||||
| NetPath Pathway | TSH Signaling Pathway | |||
| Reactome | Cell surface interactions at the vascular wall | |||
| WikiPathways | Cell surface interactions at the vascular wall | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. Blood. 2014 Apr 3;123(14):2209-19. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.